Clinical Trial Update: Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis [Phase 2]

View source ↗

Summary

The Phase 2 trial of ALXN2050 in adults with generalized myasthenia gravis was terminated. Results from the study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• ALXN2050

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Generalized Myasthenia Gravis, Myasthenia Gravis | Phase 2 | Status: TERMINATED | Results posted: 2025-01-09